What chemoradiotherapy options are recommended for an adult patient with metastatic myxofibrosarcoma and pleomorphic sarcoma involving the lungs?

Treatment for Metastatic Myxofibrosarcoma and Pleomorphic Sarcoma with Lung Metastases

For metastatic myxofibrosarcoma and undifferentiated pleomorphic sarcoma (UPS) with lung involvement, first-line treatment is anthracycline-based chemotherapy, specifically doxorubicin alone or combined with ifosfamide for good performance status patients, with palliative radiotherapy reserved for symptomatic sites. 1, 2, 3

First-Line Systemic Therapy

The standard approach is anthracycline-based chemotherapy 4, 1, 2, 3:

Single-Agent vs. Combination Therapy

• Doxorubicin monotherapy is the baseline standard for metastatic disease 1, 3
• Doxorubicin plus ifosfamide should be used when:
  • Patient has good performance status
  • Tumor response would provide clinical advantage (e.g., potential for subsequent metastasectomy)
  • The histology is sensitive to ifosfamide—both myxofibrosarcoma and UPS fall into this category 1, 2

The combination achieves higher response rates and longer progression-free survival compared to single-agent doxorubicin, though overall survival benefit remains unproven 4, 1, 3. For these specific histologies (myxofibrosarcoma and UPS), the combination is particularly appropriate given their documented ifosfamide sensitivity 2.

Important Caveat

Gemcitabine/docetaxel is not recommended as first-line therapy—a phase III trial showed no improvement in progression-free survival or response rate compared to doxorubicin 1, 3.

Role of Surgery for Lung Metastases

Surgery should be considered only if 4, 1, 2, 3:

• Metastases are metachronous (disease-free interval ≥1 year)
• Complete resection of all lesions is feasible
• No extrapulmonary disease exists
• Limited number of nodules (typically 3-5) 2

For synchronous lung metastases (as implied by your question), chemotherapy is the standard treatment 4, 1, 3. Surgery may be considered after chemotherapy only if significant tumor response is achieved and complete resection becomes feasible.

Chemotherapy before surgery is preferred when surgery is planned, as it allows assessment of tumor response and helps modulate treatment duration 4, 1, 3.

Second-Line Options

After anthracycline failure, histology-specific options for both myxofibrosarcoma and UPS include 2:

Preferential choices:

• Gemcitabine combinations (gemcitabine/docetaxel)
• Trabectedin
• High-dose ifosfamide (12-14 g/m²) if not previously used at adequate doses

Less preferential:

• Pazopanib (particularly for UPS)
• Standard-dose ifosfamide (if not used first-line)

Role of Radiotherapy

Radiotherapy in metastatic disease is palliative only 4, 1:

• Use for symptomatic bone lesions at risk of fracture
• Consider stereotactic radiotherapy for oligometastatic sites after multidisciplinary discussion 2
• Not part of standard chemoradiotherapy protocols for metastatic soft tissue sarcoma

Critical Distinction

The term "chemoradiotherapy" does not apply to standard metastatic sarcoma management. Concurrent chemoradiation is used for localized disease (preoperative or postoperative settings), not for established metastatic disease 4, 1. The case report of pulmonary sarcomatoid carcinoma treated with chemoradiotherapy 5 involves a completely different disease entity (lung cancer, not soft tissue sarcoma) and should not guide treatment decisions here.

Practical Algorithm

1. Confirm isolated lung metastases with abdominal CT and bone scan/PET 4, 1

2. Assess resectability and timing:

   • If metachronous (≥1 year disease-free) + completely resectable + limited number → Consider surgery with perioperative chemotherapy
   • If synchronous or unresectable → Proceed to chemotherapy

3. Select chemotherapy based on performance status:

   • Good PS → Doxorubicin + ifosfamide (both histologies are ifosfamide-sensitive)
   • Poor PS or cardiac contraindications → Doxorubicin alone

4. Reassess after 2-3 cycles:

   • If significant response achieved and lesions now resectable → Consider metastasectomy
   • If stable/responding → Continue to maximum doxorubicin dose or progression
   • If progression → Switch to second-line therapy

5. Use palliative RT only for symptomatic sites (bone lesions, painful masses)

Key Pitfalls to Avoid

• Do not use gemcitabine/docetaxel first-line—it failed to show benefit over doxorubicin in phase III trial 1, 3
• Do not attempt surgery for synchronous metastases without chemotherapy first 4, 1
• Do not use concurrent chemoradiation as if treating localized disease—this is metastatic disease requiring systemic therapy
• Do not use standard-dose ifosfamide if combination therapy is chosen—adequate dosing (with doxorubicin) is essential for these histologies 1, 2

The evidence consistently shows that for metastatic myxofibrosarcoma and UPS with lung involvement, systemic chemotherapy is the cornerstone of treatment, with surgery reserved for highly selected cases and radiotherapy used only for palliation of specific symptomatic sites.